prednisone has been researched along with mdv 3100 in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (54.00) | 24.3611 |
| 2020's | 23 (46.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petrylak, DP | 1 |
| Al-Asaaed, S; Winquist, E | 1 |
| Hoffman-Censits, J; Kelly, WK | 1 |
| Aebersold, D; Attard, G; Cassoly, E; Clarke, NW; de Bono, JS; Dearnaley, DP; James, ND; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MK; Ritchie, AW; Russell, JM; Schiavone, F; Spears, MR; Sydes, MR; Thalmann, G | 1 |
| Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Beuzeboc, P; Massard, C | 1 |
| Ellis, LA; Lefebvre, P; Pilon, D; Queener, M | 1 |
| Gschwend, J; Miller, K; Wolff, JM | 1 |
| Cicero, G; DE Luca, R; Dieli, F; Dorangricchia, P | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB; Yu, MK | 1 |
| Bracarda, S; Crucitta, S; Danesi, R; De Souza, P; Del Re, M; Derosa, L; Fogli, S; Massari, F; Santini, D | 1 |
| Baron, B; Chowdhury, S; de Bono, JS; Elliott, T; Feyerabend, S; Fizazi, K; Grande, E; Hirmand, M; Melhem-Bertrandt, A; Werbrouck, P | 1 |
| Fujii, Y; Saito, K | 1 |
| de Reijke, TM; Poorthuis, MHF; van Moorselaar, RJA; Vernooij, RWM | 1 |
| Barata, PC; Edwin, NC; Emamekhoo, H; Garcia, JA; Grivas, P; Woo, KM | 1 |
| Artenie, C; Dearden, L; Gater, A; Grant, L; Jackson, C; Mills, A; Shalet, N | 1 |
| Chi, KN; Eigl, BJ; Finch, DL; Gleave, ME; Ivanov, N; Khalaf, DJ; Kollmannsberger, CK; Oja, C; Sunderland, K; Vergidis, J; Zulfiqar, M | 1 |
| Morgans, AK; Ryan, CJ | 1 |
| Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z | 1 |
| Beijnen, JH; Rosing, H; van Nuland, M; van Rossum, HH; Venekamp, N; Wouters, WME | 1 |
| George, DJ | 1 |
| Gervasi, L; McGowan, T; Mehlhaff, B; Pei, H; Phillips, J; Saltzstein, D; Shore, ND; Sieber, P; Wong, YN | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Beal-Ardisson, D; Birtle, A; Dourthe, LM; Lagneau, E; Lefresne, F; Lukac, M; Pintus, E; Pissart, G; Ploussard, G; Poulsen, MH; Reid, A; Thiery-Vuillemin, A; Trepiakas, R; Van Sanden, S | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Annala, M; Attwell, A; Azad, AA; Chi, KN; Eigl, BJ; Ellard, SL; Finch, DL; Gleave, ME; Keith, B; Khalaf, DJ; Kollmannsberger, CK; Le, L; Noonan, K; Oja, C; Sunderland, K; Taavitsainen, S; Vergidis, J; Wadhwa, D; Wyatt, AW; Zulfiqar, M | 1 |
| Sidaway, P | 1 |
| Tombal, B | 1 |
| Fong, L; Nicholson, LT | 1 |
| Baser, O; George, DJ; Huang, A; Lechpammer, S; Mardekian, J; Ramaswamy, K; Sandin, R; Schultz, NM; Wang, L | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Eterović, D; Omrčen, T; Vrdoljak, E | 1 |
| Amaravadi, R; Black, TA; Buckingham, TH; Calara-Nielsen, K; Carpenter, EL; Cherkas, Y; Foulk, B; Gross, S; Haas, NB; He, M; Jones, JO; LaRiviere, MJ; Long, Q; Majmundar, KJ; Min, EJ; Pal, SK; Patel, J; Savitch, SL; Smirnov, D; Vaughn, DJ; Wellen, KE; Yee, SS | 1 |
| Asensio, I; Casado, MA; Cassinello, J; Domínguez-Lubillo, T; Gómez-Barrera, M; Hernando, T; Moreno, P; Parra, R | 1 |
| Bhak, RH; Freedland, SJ; Lefebvre, P; Li, S; Narkhede, S; Pilon, D; Young-Xu, Y | 1 |
| Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ | 1 |
| Bratt, O; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Nolsøe, AB; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB | 1 |
| Annala, M; Azad, AA; Bacon, JVW; Beja, K; Chi, KN; Ferrario, C; Fu, S; Gingerich, JR; Hotte, SJ; Iqbal, N; Kallio, HML; Khalaf, DJ; Lo, G; North, SA; Nykter, M; Ong, M; Pezaro, CJ; Ruether, JD; Schönlau, E; Sipola, J; Sridhar, SS; Taavitsainen, S; Tran, B; Vandekerkhove, G; Wadhwa, D; Wong, A; Wood, LA; Wyatt, AW | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Aglietta, M; Aieta, M; Bozza, G; Buti, S; Caffo, O; Carrozza, F; Ciccarese, C; D'Angelo, A; De Giorgi, U; Ermacora, P; Facchini, G; Fratino, L; Galli, L; Gasparro, D; Giordano, M; Iacovelli, R; Kinspergher, S; Lippe, P; Lo Re, G; Maines, F; Maruzzo, M; Messina, C; Morelli, F; Mucciarini, C; Nicodemo, M; Nolè, F; Ortega, C; Palesandro, E; Pappagallo, G; Porta, C; Razzini, G; Rossetti, S; Sabbatini, R; Sartori, D; Scapoli, D; Schepisi, G; Valcamonico, F; Veccia, A; Verri, E; Vittimberga, I; Zagonel, V | 1 |
| Agarwal, N; Bruno, A; George, D; Guo, H; Higano, CS; Jiao, X; Miller, K; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
| Bisbjerg, R; Faber, J; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB | 1 |
| Fiala, O; Finek, J; Hora, M; Hosek, P; Kolar, J; Korunkova, H; Sedlackova, H; Sorejs, O; Topolcan, O; Travnicek, I; Windrichova, J | 1 |
| Andrade, LMQS; De Giorgi, U; Fornarini, G; Fotia, G; Francini, E; Malgeri, A; Mestre, RP; Modesti, M; Nuzzo, PV; Patrikidou, A; Pederzoli, F; Pignata, S; Procopio, G; Rossetti, S; Russo, A; Saieva, C; Valenca Bueno, L; Zanardi, E | 1 |
| Antonarakis, ES; Armstrong, AJ; Beltran, H; Beumer, JH; Bobek, O; Bryce, AH; Goldkorn, A; Hahn, O; Halabi, S; Heller, G; Hillman, DW; Langevin, B; Lewis, LD; McGary, EC; Mehan, PT; Morris, MJ; Roth, BJ; Ryan, C; Schwartz, L; Small, EJ; Taplin, ME; Watt, C; Xiao, H | 1 |
| Antonarakis, ES; Begbie, SD; Chiu, KY; De Santis, M; Fong, PC; Gafanov, RA; Goh, JC; Greil, R; Huang, YH; Kim, J; Kolinsky, MP; Kramer, G; Lee, JL; Massari, F; McDermott, R; Mehra, N; Park, SH; Poehlein, CH; Qiu, P; Retz, M; Rey, F; Rosenbaum, E; Roubaud, G; Sade, JP; Sala-Gonzalez, N; Shin, SJ; Sumitomo, M; Suzuki, H; Yanez, P; Yu, EY; Zhang, J | 1 |
| Beckstead, R; Cutshall, ZA; Dougherty, M; Haaland, B; Kohli, M; Kohli, R; Nelson, RE; Yoo, M | 1 |
| Adachi, T; Azuma, H; Fukuokaya, W; Hashimoto, T; Hirasawa, Y; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Maenosono, R; Mori, K; Nakamori, K; Nishimura, K; Ohno, T; Ohno, Y; Saruta, M; Shiroki, R; Takahara, K; Tokushige, S; Tsujino, T; Tsuzuki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yamazaki, S; Yanagisawa, T; Yoshizawa, A | 1 |
12 review(s) available for prednisone and mdv 3100
| Article | Year |
|---|---|
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Secondary hormonal manipulation in castration resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2014 |
Practical guide to the use of enzalutamide.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2014 |
[How to manage patients with CRPC?].
Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts | 2015 |
[Strategies for First-Line Treatment of mCRPC].
Topics: Androstenes; Benzamides; Drug Therapy, Combination; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2016 |
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Topics: Abiraterone Acetate; Antineoplastic Agents; Benzamides; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Male; Nitriles; Phenylthiohydantoin; Polypharmacy; Prednisone; Prostatic Neoplasms | 2017 |
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2017 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Bayes Theorem; Cost-Effectiveness Analysis; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
16 trial(s) available for prednisone and mdv 3100
| Article | Year |
|---|---|
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Research Design; Steroid 17-alpha-Hydroxylase; Switzerland; Treatment Outcome; United Kingdom | 2014 |
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Taxoids; Treatment Outcome | 2017 |
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Humans; Kallikreins; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; United States | 2019 |
Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).
Topics: Abiraterone Acetate; Affect; Aged; Aged, 80 and over; Amnesia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Caregivers; Cognitive Dysfunction; Confusion; Fatigue; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2019 |
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2019 |
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Reported Outcome Measures; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors | 2020 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2019 |
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Tomography, X-Ray Computed | 2021 |
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2021 |
Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diabetes Mellitus, Type 2; Fatigue; Glycated Hemoglobin; Hot Temperature; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2022 |
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Disease-Free Survival; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
22 other study(ies) available for prednisone and mdv 3100
| Article | Year |
|---|---|
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2016 |
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Signal Transduction; Steroid Synthesis Inhibitors; Time Factors; Treatment Outcome | 2017 |
Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
Topics: Abiraterone Acetate; Benzamides; Europe; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2018 |
Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatigue; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Patient Satisfaction; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Qualitative Research; Quality of Life | 2019 |
Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making.
Topics: Androstenes; Benzamides; Decision Making; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
Topics: Abiraterone Acetate; Androstenedione; Benzamides; Chromatography, Liquid; Dihydrotestosterone; Humans; Hydrocortisone; Male; Nitriles; Phenylthiohydantoin; Plasma; Prednisone; Prostatic Neoplasms, Castration-Resistant; Tandem Mass Spectrometry; Testosterone | 2019 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Sequence of AR inhibitors affects outcome.
Topics: Abiraterone Acetate; Benzamides; Cross-Over Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2020 |
Androgen receptor-targeted agents in the management of advanced prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Cross-Over Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2019 |
Immune Checkpoint Inhibition in Prostate Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms | 2020 |
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Topics: Abiraterone Acetate; Adult; Aged; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cohort Studies; Drug Administration Schedule; Health Care Costs; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptome | 2021 |
Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Veterans | 2021 |
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Benzamides; Bone Neoplasms; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |